{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T11:56:56Z","timestamp":1784289416738,"version":"3.55.0"},"reference-count":86,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.drudis.2026.104597","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T16:11:44Z","timestamp":1767715904000},"page":"104597","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Gaining regulatory acceptance for novel technologies in nonclinical drug development: A scoping review of its conceptualization in scientific literature"],"prefix":"10.1016","volume":"31","author":[{"given":"Ivar T.","family":"van der Zee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce M.","family":"Hoek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarno","family":"Hoekman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie L.","family":"De Bruin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2026.104597_b0005","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nrd3681","article-title":"Diagnosing the decline in pharmaceutical R&D efficiency","volume":"11","author":"Scannell","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2026.104597_b0010","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s43546-021-00163-5","article-title":"Innovation crisis in the pharmaceutical industry? A survey","volume":"1","author":"Laermann-Nguyen","year":"2021","journal-title":"SN Bus Econ"},{"key":"10.1016\/j.drudis.2026.104597_b0015","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jhealeco.2016.01.012","article-title":"Innovation in the pharmaceutical industry: new estimates of R&D costs","volume":"47","author":"DiMasi","year":"2016","journal-title":"J Health Econ"},{"key":"10.1016\/j.drudis.2026.104597_b0020","unstructured":"Clinical and Translational Science Awards (CTSA) Program. National Center for Advancing Translational Sciences. Accessed 1 July 2024. https:\/\/ncats.nih.gov\/research\/research-activities\/ctsa."},{"key":"10.1016\/j.drudis.2026.104597_b0025","unstructured":"KNAW. Efficiency gains through innovation in medicines development: how can science contribute? KNAW. Accessed 1 July 2024. https:\/\/storage.knaw.nl\/2022-06\/20211005-Advies-Eficiency-through-innovation-web."},{"key":"10.1016\/j.drudis.2026.104597_b0030","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s41231-019-0050-7","article-title":"Lost in translation: the valley of death across preclinical and clinical divide \u2013 identification of problems and overcoming obstacles","volume":"4","author":"Seyhan","year":"2019","journal-title":"Transl Med Commun"},{"key":"10.1016\/j.drudis.2026.104597_b0035","article-title":"New approach methodologies (NAMs): identifying and overcoming hurdles to accelerated adoption","volume":"13","author":"Sewell","year":"2024","journal-title":"Toxicol Res (Camb)"},{"key":"10.1016\/j.drudis.2026.104597_b0040","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/s41416-019-0672-6","article-title":"Patient-derived explants (PDEs) as a powerful preclinical platform for anti-cancer drug and biomarker discovery","volume":"122","author":"Powley","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.drudis.2026.104597_b0045","unstructured":"The use of Artificial Intelligence (AI) in the medicinal product lifecycle. European Medicines Agency. Accessed 8 April 2024. https:\/\/www.ema.europa.eu\/en\/use-artificial-intelligence-ai-medicinal-product-lifecycle#current-version-10218."},{"key":"10.1016\/j.drudis.2026.104597_b0050","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.drudis.2020.10.010","article-title":"Artificial intelligence in drug discovery and development","volume":"26","author":"Paul","year":"2020","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2026.104597_b0055","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.14139","article-title":"Use of artificial intelligence in drug development","volume":"7","author":"Druedahl","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.drudis.2026.104597_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2023.105345","article-title":"Gaps and challenges in nonclinical assessments of pharmaceuticals: an FDA\/CDER perspective on considerations for development of new approach methodologies","volume":"139","author":"Avila","year":"2023","journal-title":"Regul Toxicol Pharmacol"},{"key":"10.1016\/j.drudis.2026.104597_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2024.105683","article-title":"Endeavours made by trade associations, pharmaceutical companies and regulators in the replacement, reduction and refinement of animal experimentation in safety testing of pharmaceuticals","volume":"152","author":"Harrell","year":"2024","journal-title":"Regul Toxicol Pharmacol"},{"key":"10.1016\/j.drudis.2026.104597_b0070","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/cpt.136","article-title":"Biomarker qualification: toward a multiple stakeholder framework for biomarker development, regulatory acceptance, and utilization","volume":"98","author":"Amur","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.drudis.2026.104597_b0075","series-title":"Validation of Alternative Methods for Toxicity Testing","first-page":"33","article-title":"Regulatory acceptance of alternative methods in the development and approval of pharmaceuticals","author":"Beken","year":"2016"},{"key":"10.1016\/j.drudis.2026.104597_b0080","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00204-018-2152-9","article-title":"Innovative organotypic in vitro models for safety assessment: aligning with regulatory requirements and understanding models of the heart, skin, and liver as paradigms","volume":"92","author":"Pridgeon","year":"2018","journal-title":"Arch Toxicol"},{"key":"10.1016\/j.drudis.2026.104597_b0085","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/cpt.2609","article-title":"Biomarker qualification at the European Medicines Agency: a look under the hood","volume":"112","author":"Berman","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.drudis.2026.104597_b0090","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ejps.2016.06.006","article-title":"Use of physiologically relevant biopharmaceutics tools within the pharmaceutical industry and in regulatory sciences: where are we now and what are the gaps?","volume":"91","author":"Flanagan","year":"2016","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.drudis.2026.104597_b0095","doi-asserted-by":"crossref","first-page":"287","DOI":"10.14573\/altex.2012.3.287","article-title":"Regulatory acceptance and use of 3R models: a multilevel perspective","volume":"29","author":"Schiffelers","year":"2012","journal-title":"ALTEX"},{"key":"10.1016\/j.drudis.2026.104597_b0100","article-title":"Considerations from an international regulatory and pharmaceutical industry (IQ MPS Affiliate) workshop on the standardization of complex in vitro models in drug development","volume":"8","author":"Tomlinson","year":"2024","journal-title":"Adv Biol (Weinh)"},{"key":"10.1016\/j.drudis.2026.104597_b0105","unstructured":"Commissioner O of the. FDA Center\/Office Regulatory Science Research Priority Areas for CERSI Program. FDA. Published online 31 January 2025. Accessed 2 April 2025. https:\/\/www.fda.gov\/science-research\/advancing-regulatory-science\/fda-centeroffice-regulatory-science-research-priority-areas-cersi-program."},{"key":"10.1016\/j.drudis.2026.104597_b0110","unstructured":"EMA. Regulatory Science Research Needs (EMA\/510633\/2024) 2024 update \u2013 DRAFT. Published online 13 November 2024. Accessed 4 February 2025. https:\/\/www.ema.europa.eu\/en\/documents\/other\/draft-regulatory-science-research-needs-2024-update_en.pdf?mc_cid=4bf8fcd429."},{"key":"10.1016\/j.drudis.2026.104597_b0115","series-title":"Seizing Opportunities in a Changing Medicines Landscape: The European Medicines Agencies Network Strategy 2028","author":"European Medicines Agency","year":"2025"},{"key":"10.1016\/j.drudis.2026.104597_b0120","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/cpt.622","article-title":"Impact of physiologically based pharmacokinetic models on regulatory reviews and product labels: frequent utilization in the field of oncology","volume":"101","author":"Yoshida","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.drudis.2026.104597_b0125","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/cpt.539","article-title":"Physiologically based pharmacokinetic modeling in regulatory decision-making at the European Medicines Agency","volume":"102","author":"Luzon","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.drudis.2026.104597_b0130","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/cpt.2554","article-title":"Biomarker qualification at the European Medicines Agency: a review of biomarker qualification procedures from 2008 to 2020","volume":"112","author":"Bakker","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.drudis.2026.104597_b0135","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s11024-017-9326-0","article-title":"Stretching and challenging the boundaries of law: varieties of knowledge in biotechnologies regulation","volume":"55","author":"Faulkner","year":"2017","journal-title":"Minerva"},{"key":"10.1016\/j.drudis.2026.104597_b0140","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s11024-017-9324-2","article-title":"Opening the regulatory black box of clinical cancer research: transnational expertise networks and \u201cdisruptive\u201d technologies","volume":"55","author":"Cambrosio","year":"2017","journal-title":"Minerva"},{"key":"10.1016\/j.drudis.2026.104597_b0145","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1177\/0306312702032003001","article-title":"Progress, innovation and regulatory science in drug development: the politics of international standard-setting","volume":"32","author":"Abraham","year":"2002","journal-title":"Soc Stud Sci"},{"key":"10.1016\/j.drudis.2026.104597_b0150","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s11024-017-9325-1","article-title":"Expertise, regulatory science and the evaluation of technology and risk: introduction to the special issue","volume":"55","author":"Demortain","year":"2017","journal-title":"Minerva"},{"key":"10.1016\/j.drudis.2026.104597_b0155","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1177\/0162243911424914","article-title":"The neoliberal regulatory state, industry interests, and the ideological penetration of scientific knowledge: deconstructing the redefinition of carcinogens in pharmaceuticals","volume":"37","author":"Abraham","year":"2012","journal-title":"Sci Technol Human Values"},{"key":"10.1016\/j.drudis.2026.104597_b0160","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/toxsci\/kfae122","article-title":"An industry perspective on the FDA Modernization Act 2.0\/3.0: potential next steps for sponsors to reduce animal use in drug development","volume":"203","author":"Carratt","year":"2025","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.drudis.2026.104597_b0165","unstructured":"Therapeutic Goods Administration. Regulatory Science Strategy 2020\u20132025. Published online November 2019. Accessed 12 October 2025. https:\/\/www.tga.gov.au\/sites\/default\/files\/health-products-regulation-group-regulatory-science-strategy-2020-2025.pdf."},{"key":"10.1016\/j.drudis.2026.104597_b0170","series-title":"The Coding Manual for Qualitative Researchers","author":"Saldana","year":"2015"},{"key":"10.1016\/j.drudis.2026.104597_b0175","article-title":"A fully-open index of scholarly works, authors, venues, institutions, and concepts","author":"Priem","year":"2022","journal-title":"Arxiv"},{"key":"10.1016\/j.drudis.2026.104597_b0180","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1007\/s11192-025-05293-3","article-title":"Reference coverage analysis of OpenAlex compared to Web of Science and Scopus","volume":"130","author":"Culbert","year":"2025","journal-title":"Scientometrics"},{"key":"10.1016\/j.drudis.2026.104597_b0185","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s42256-020-00287-7","article-title":"An open source machine learning framework for efficient and transparent systematic reviews","volume":"3","author":"van de Schoot","year":"2021","journal-title":"Nat Mach Intell"},{"key":"10.1016\/j.drudis.2026.104597_b0190","unstructured":"Melkschuimer\/vanderzee-2025-regulatory-acceptance-review: code for the literature search performed in Van der Zee et al. (2025), \u201cGaining regulatory acceptance for novel technologies...\u201d Accessed 13 October 2025. https:\/\/github.com\/Melkschuimer\/vanderzee-2025-regulatory-acceptance-review."},{"key":"10.1016\/j.drudis.2026.104597_b0195","unstructured":"VERBI Software. MAXQDA 24. Published online 2023. maxqda.com."},{"key":"10.1016\/j.drudis.2026.104597_b0200","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1080\/2159676X.2019.1628806","article-title":"Reflecting on reflexive thematic analysis","volume":"11","author":"Braun","year":"2019","journal-title":"Qual Res Sport Exerc Health"},{"key":"10.1016\/j.drudis.2026.104597_b0205","series-title":"Qualitative Research Methods","author":"Hennink","year":"2020"},{"key":"10.1016\/j.drudis.2026.104597_b0210","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jcmgh.2018.08.004","article-title":"Advancing regulatory science through innovation: in vitro microphysiological systems","volume":"7","author":"Fitzpatrick","year":"2019","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1016\/j.drudis.2026.104597_b0215","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.taap.2005.02.024","article-title":"Alternatives to animal experimentation: the regulatory background","volume":"207","author":"Garthoff","year":"2005","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.drudis.2026.104597_b0220","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s10928-024-09905-y","article-title":"An industry perspective on current QSP trends in drug development","volume":"51","author":"Cucurull-Sanchez","year":"2024","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.drudis.2026.104597_b0225","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.comtox.2019.01.002","article-title":"An international effort to promote the regulatory use of PBK models based on non-animal data","volume":"11","author":"Sachana","year":"2019","journal-title":"Comput Toxicol"},{"key":"10.1016\/j.drudis.2026.104597_b0230","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1177\/0960327115598410","article-title":"Animals and the 3Rs in toxicology research and testing: the way forward","volume":"34","author":"Stokes","year":"2015","journal-title":"Hum Exp Toxicol"},{"key":"10.1016\/j.drudis.2026.104597_b0235","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1080\/10915810590948352","article-title":"Application of emerging technologies in toxicology and safety assessment: regulatory perspectives","volume":"24","author":"Leighton","year":"2005","journal-title":"Int J Toxicol"},{"key":"10.1016\/j.drudis.2026.104597_b0240","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/978-1-60327-048-9_12","article-title":"Applications of toxicogenomics to nonclinical drug development: regulatory science considerations","volume":"460","author":"Sistare","year":"2008","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.drudis.2026.104597_b0245","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1177\/026119291504300504","article-title":"Barriers to the uptake of human-based test methods, and how to overcome them","volume":"43","author":"Archibald","year":"2015","journal-title":"Altern Lab Anim"},{"key":"10.1016\/j.drudis.2026.104597_b0250","first-page":"365","article-title":"Biology-inspired microphysiological systems to advance medicines for patient benefit and animal welfare","volume":"37","author":"Marx","year":"2020","journal-title":"ALTEX"},{"key":"10.1016\/j.drudis.2026.104597_b0255","doi-asserted-by":"crossref","DOI":"10.3389\/ftox.2022.903027","article-title":"Brazil\u2019s regulatory context for using new approach methodologies (NAMs) on the registration of products","volume":"4","author":"Villela","year":"2022","journal-title":"Front Toxicol"},{"key":"10.1016\/j.drudis.2026.104597_b0260","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1517\/17460441.2012.679615","article-title":"Challenges of biomarkers in drug discovery and development","volume":"7","author":"Goodsaid","year":"2012","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.drudis.2026.104597_b0265","series-title":"Drug Discovery Toxicology","first-page":"1","article-title":"Emerging technologies and their role in regulatory review","author":"Colatsky","year":"2016"},{"key":"10.1016\/j.drudis.2026.104597_b0270","doi-asserted-by":"crossref","DOI":"10.1289\/EHP1435","article-title":"Has toxicity testing moved into the 21st century? A survey and analysis of perceptions in the field of toxicology","volume":"125","author":"Zaunbrecher","year":"2017","journal-title":"Environ Health Perspect"},{"key":"10.1016\/j.drudis.2026.104597_b0275","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.yrtph.2015.07.022","article-title":"Impact analysis of ICH S9 on non-clinical development of anticancer drugs","volume":"73","author":"Bonelli","year":"2015","journal-title":"Regul Toxicol Pharmacol"},{"key":"10.1016\/j.drudis.2026.104597_b0280","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ymeth.2020.01.011","article-title":"In silico trials: verification, validation and uncertainty quantification of predictive models used in the regulatory evaluation of biomedical products","volume":"185","author":"Viceconti","year":"2021","journal-title":"Methods"},{"key":"10.1016\/j.drudis.2026.104597_b0285","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.yrtph.2017.08.019","article-title":"Investigating the state of physiologically based kinetic modelling practices and challenges associated with gaining regulatory acceptance of model applications","volume":"90","author":"Paini","year":"2017","journal-title":"Regul Toxicol Pharmacol"},{"key":"10.1016\/j.drudis.2026.104597_b0290","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.yrtph.2015.07.007","article-title":"Knowledge sharing to facilitate regulatory decision-making in regard to alternatives to animal testing: report of an EPAA workshop","volume":"73","author":"Ramirez","year":"2015","journal-title":"Regul Toxicol Pharmacol"},{"key":"10.1016\/j.drudis.2026.104597_b0295","doi-asserted-by":"crossref","first-page":"20S","DOI":"10.1177\/0091270010377628","article-title":"Model\u2010based drug development survey finds pharmacometrics impacting decision making in the pharmaceutical industry","volume":"50","author":"Stone","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.drudis.2026.104597_b0300","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/psp4.12372","article-title":"Model\u2010informed drug discovery and development: current industry good practice and regulatory expectations and future perspectives","volume":"8","author":"Marshall","year":"2019","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.drudis.2026.104597_b0305","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/prca.201000130","article-title":"New pathway for qualification of novel methodologies in the European Medicines Agency","volume":"5","author":"Manolis","year":"2011","journal-title":"Proteomics Clin Appl"},{"key":"10.1016\/j.drudis.2026.104597_b0310","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.drudis.2014.01.002","article-title":"Overcoming the barriers to the uptake of nonclinical microsampling in regulatory safety studies","volume":"19","author":"Chapman","year":"2014","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2026.104597_b0315","first-page":"297","article-title":"Perspectives on the evaluation and adoption of complex in vitro models in drug development: workshop with the FDA and the pharmaceutical industry (IQ MPS Affiliate)","volume":"39","author":"Baran","year":"2022","journal-title":"ALTEX"},{"key":"10.1016\/j.drudis.2026.104597_b0320","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1177\/0091270003252244","article-title":"Pharmacogenetics and pharmacogenomics in drug development and regulatory decision making: report of the first FDA\u2010PWG\u2010PhRMA\u2010DruSafe Workshop","volume":"43","author":"Lesko","year":"2003","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.drudis.2026.104597_b0325","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.xphs.2018.10.033","article-title":"Physiologically based pharmacokinetic modeling in regulatory science: an update from the U.S. Food and Drug Administration\u2019s Office of clinical pharmacology","volume":"108","author":"Grimstein","year":"2019","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.drudis.2026.104597_b0330","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1002\/jcph.1654","article-title":"Physiologically based pharmacokinetics as a component of model\u2010informed drug development: where we were, where we are, and where we are heading","volume":"60","author":"Rostami-Hodjegan","year":"2020","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.drudis.2026.104597_b0335","first-page":"89","article-title":"Progress in establishing in vitro alternatives to animal experiments \u2013 ethical and scientific challenges","volume":"11","author":"Spielmann","year":"2005","journal-title":"JSAAE"},{"key":"10.1016\/j.drudis.2026.104597_b0340","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/ilar\/ilw032","article-title":"Promoting adoption of the 3Rs through regulatory qualification","volume":"57","author":"Walker","year":"2016","journal-title":"ILAR J"},{"key":"10.1016\/j.drudis.2026.104597_b0345","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1124\/pharmrev.123.000967","article-title":"Protecting human and animal health: the road from animal models to new approach methods","volume":"76","author":"Kaplan","year":"2024","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.drudis.2026.104597_b0350","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.cotox.2017.06.011","article-title":"Qualification of safety biomarkers for use in drug development: what has been achieved and what is the path forward?","volume":"4","author":"Harpur","year":"2017","journal-title":"Curr Opin Toxicol"},{"key":"10.1016\/j.drudis.2026.104597_b0355","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.vascn.2010.05.005","article-title":"Regulatory acceptability of the minipig in the development of pharmaceuticals, chemicals and other products","volume":"62","author":"van der Laan","year":"2010","journal-title":"J Pharmacol Toxicol Methods"},{"key":"10.1016\/j.drudis.2026.104597_b0360","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.yrtph.2014.02.007","article-title":"Regulatory acceptance and use of 3R models for pharmaceuticals and chemicals: expert opinions on the state of affairs and the way forward","volume":"69","author":"Schiffelers","year":"2014","journal-title":"Regul Toxicol Pharmacol"},{"key":"10.1016\/j.drudis.2026.104597_b0365","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1080\/13511610.2012.726423","article-title":"Regulatory experiments and transnational networks: the governance of pharmacogenomics in Europe and the United States","volume":"25","author":"Hogarth","year":"2012","journal-title":"Innov Eur J Soc Sci Res"},{"key":"10.1016\/j.drudis.2026.104597_b0370","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.yrtph.2006.06.001","article-title":"Report of an ISRTP Workshop: progress and barriers to incorporating alternative toxicological methods in the U.S","volume":"46","author":"Becker","year":"2006","journal-title":"Regul Toxicol Pharmacol"},{"key":"10.1016\/j.drudis.2026.104597_b0375","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.yrtph.2017.07.001","article-title":"Steps towards the international regulatory acceptance of non-animal methodology in safety assessment","volume":"89","author":"Sewell","year":"2017","journal-title":"Regul Toxicol Pharmacol"},{"key":"10.1016\/j.drudis.2026.104597_b0380","doi-asserted-by":"crossref","first-page":"411","DOI":"10.4155\/bio.12.329","article-title":"Strategic regulatory approaches for the qualification of a biomarker assay for safety use","volume":"5","author":"Valeri","year":"2013","journal-title":"Bioanalysis"},{"key":"10.1016\/j.drudis.2026.104597_b0385","doi-asserted-by":"crossref","DOI":"10.4155\/fsoa-2017-0002","article-title":"The ascendance of microphysiological systems to solve the drug testing dilemma","volume":"3","author":"Dehne","year":"2017","journal-title":"Future Sci OA"},{"key":"10.1016\/j.drudis.2026.104597_b0390","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1177\/026119290403201s109","article-title":"The FDA\u2019s regulatory role in the ICCVAM process","volume":"32","author":"Schechtman","year":"2004","journal-title":"Altern Lab Anim"},{"key":"10.1016\/j.drudis.2026.104597_b0395","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1177\/026119290102900512","article-title":"The role of ECVAM in promoting the regulatory acceptance of alternative methods in the European Union","volume":"29","author":"Worth","year":"2001","journal-title":"Altern Lab Anim"},{"key":"10.1016\/j.drudis.2026.104597_b0400","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.vascn.2018.05.003","article-title":"The use of human tissue in safety assessment","volume":"93","author":"Jackson","year":"2018","journal-title":"J Pharmacol Toxicol Methods"},{"key":"10.1016\/j.drudis.2026.104597_b0405","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1177\/2168479017720249","article-title":"Translating new science into the drug review process: the US FDA\u2019s division of applied regulatory science","volume":"52","author":"Rouse","year":"2018","journal-title":"Ther Innov Regul Sci"},{"key":"10.1016\/j.drudis.2026.104597_b0410","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202006027","article-title":"Understanding the development, standardization, and validation process of alternative in vitro test methods for regulatory approval from a researcher perspective","volume":"17","author":"Bas","year":"2021","journal-title":"Small"},{"key":"10.1016\/j.drudis.2026.104597_b0415","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1017\/S0266462323000375","article-title":"Uncertainty management in regulatory and health technology assessment decision-making on drugs: guidance of the HTAi-DIA Working Group","volume":"39","author":"Hogervorst","year":"2023","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.drudis.2026.104597_b0420","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1177\/030631289019003001","article-title":"Institutional ecology, \u2018translations\u2019 and boundary objects: amateurs and professionals in Berkeley\u2019s Museum of Vertebrate Zoology, 1907\u201339","volume":"19","author":"Star","year":"1989","journal-title":"Soc Stud Sci"},{"key":"10.1016\/j.drudis.2026.104597_b0425","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1748-5908-4-50","article-title":"Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science","volume":"4","author":"Damschroder","year":"2009","journal-title":"Implement Sci"},{"key":"10.1016\/j.drudis.2026.104597_b0430","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1016\/j.enpol.2006.12.001","article-title":"Social acceptance of renewable energy innovation: an introduction to the concept","volume":"35","author":"W\u00fcstenhagen","year":"2007","journal-title":"Energy Policy"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626000024?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626000024?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T07:22:36Z","timestamp":1773991356000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644626000024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":86,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1359644626000024"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104597","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gaining regulatory acceptance for novel technologies in nonclinical drug development: A scoping review of its conceptualization in scientific literature","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104597","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104597"}}